Aernout van Haarst, PhD

Director, Scientific Affairs at Celerion

As Director, Scientific Affairs, Dr. Aernout van Haarst plays a key role in leveraging Celerion’s scientific and drug development expertise to support drug development programs of Celerion’s clients. He is a member of Celerion’s respiratory and vaccine research teams and is the scientific liaison to various external experts in the fields of pulmonology and vaccine development.

Dr. van Haarst has over 20 year of drug development experience at biotechnology companies as well as CROs. This experience includes designing drug development strategies as well as hands-on experience in the design and conduct of early clinical studies in a breadth of therapeutic areas, and all clinical operational management including regulatory authority meetings.

Dr. van Haarst earned his doctorate in Pharmacology from the School of Medicine at Leiden University (Netherlands) and also qualified as Clinical Pharmacologist in Leiden. He holds a Master’s Degree in Medical Biology, from the School of Medicine at Utrecht University (Netherlands).

Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD_Profile

Early Phase Clinical Trials for Inhaled Drugs - Challenges and Opportunities

  • Considerations for development of inhaled drugs
  • Rationale for inclusion of patients in early clinical development
  • Operational hurdles for (hybrid) Phase I studies involving patients

Other Speakers from the IRDD Summit 2020

Mark Milton-Edwards

Head of Product & Health Solutions at Teva

Diana Fernandes

Inhaled Biopharmaceutical Development Scientist at Hovione

Dino Farina

Founder and CEO at Proveris Scientific